Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

Inclusion Criteria Groups 1-5: * Bacteriologically confirmed rifampicin-susceptible pulmonary TB using phenotypic drug susceptibility testing or a World Health Organization (WHO) approved molecular test. * Documentation of HIV status as positive or negative by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit. * For individuals with HIV, on locally approved HIV ART for at least 90 days prior to entry. * For individuals with HIV, CD4+ cell count ≥250 cells/mm3 obtained within 90 days prior to entry at any network-approved non-US laboratory that is DAIDS IQA certified. * For individuals with HIV, HIV-1 RNA below the limit of detection obtained within 90 days prior to entry by any network-approved laboratory outside the US that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs. * Laboratory values within the indicated ranges, obtained within 14 days prior to entry by any network-approved laboratory outside the US that operates in accordance with GCLP and participates in appropriate external quality assurance programs. * Absolute neutrophil count (ANC) ≥800 cells/mm3 * Hemoglobin ≥8.5 g/dL for candidates assigned female sex at birth and \>9.0 g/dL for candidates assigned male sex at birth * Platelet count ≥100,000/mm3 * Serum creatinine ≤1.5 X upper limit of normal (ULN) * AST (SGOT), ALT (SGPT), and alkaline phosphatase, ≤2.5 X ULN * Tot…